Company / Return on Assets (ROA)
Vir Biotechnology, Inc. Return on Assets (ROA) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-43.7%
FY2025
5-year range
-43.7% / -8.9%
FY2021-FY2025
Trend
-17.1%
vs FY2024
Sector context
#167 of 213
Health Care
What the data says
Vir Biotechnology, Inc.'s return on assets (roa) of -43.7% is lower than 78% of companies in the Health Care sector (FY2025). Return on Assets (ROA) has declined for 4 consecutive years, from -8.9% in FY2021 to -43.7% in FY2025.
Based on SEC 10-K filings.
-43.7% in FY2025 with a 5-year CAGR of -11.2%.
Declined from -32.0% to -43.7% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -33.0pp
- 5-Year Change
- -11.2pp
- 10-Year Change
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 213This company -43.7% Sector average -24.1%
▼
-81.0% below sector average
Key checks
Key Insights
- Vir Biotechnology, Inc.'s return on assets (roa) has declined for 4 consecutive years.
- In FY2025, return on assets (roa) decreased 17.1% year-over-year.
- Currently 19.5pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -43.7% | -17.1% |
| FY2024 | -37.3% | -16.4% |
| FY2023 | -32.0% | -200.7% |
| FY2022 | -10.7% | -19.2% |
| FY2021 | -8.9% | +72.5% |
| FY2020 | -32.5% | +4.7% |
| FY2019 | -34.1% | +43.6% |
| FY2018 | -60.5% | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026